About IsoRay (NYSEAMERICAN:ISR)
IsoRay, Inc. is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The Company's Proxcelan Cesium-131 seed is classified as a Class II device.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNYSEAMERICAN:ISR
CUSIPN/A
Phone+1-509-3751202
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-95.25%
Return on Equity-69.11%
Return on Assets-58.22%
Miscellaneous
EmployeesN/A
Outstanding Shares55,100,000
IsoRay (NYSEAMERICAN:ISR) Frequently Asked Questions
What is IsoRay's stock symbol?
IsoRay trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ISR."
How were IsoRay's earnings last quarter?
IsoRay (NYSEAMERICAN:ISR) released its quarterly earnings data on Thursday, February, 8th. The healthcare company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.02) by $0.01. The healthcare company earned $1.54 million during the quarter. IsoRay had a negative net margin of 95.25% and a negative return on equity of 69.11%. View IsoRay's Earnings History.
What price target have analysts set for ISR?
2 brokerages have issued 1 year target prices for IsoRay's shares. Their predictions range from $1.00 to $2.00. On average, they anticipate IsoRay's stock price to reach $1.50 in the next year. View Analyst Ratings for IsoRay.
Who are some of IsoRay's key competitors?
Some companies that are related to IsoRay include Synthetic Biologics (SYN), Enservco (ENSV), CynergisTek (CTEK), Platinum Group Metals (PLG), VolitionRX (VNRX), Electromed (ELMD), Biopharmx (BPMX), WidePoint (WYY), IEC Electronics (IEC), Nevada Gold & Casinos (UWN), Superior Drilling (SDPI), Digital Power (DPW), Golden Minerals (AUMN), Intellicheck (IDN), Actinium Pharmaceuticals (ATNM), Can Fite Biopharma (CANF), Paramount Gold Nevada (PZG) and Solitario Zinc (XPL).
Who are IsoRay's key executives?
IsoRay's management team includes the folowing people:
- Thomas C. LaVoy, Chairman of the Board, Chief Executive Officer
- Mark John Austin, Principal Financial Officer, Principal Accounting Officer, Controller
- William Cavanagh III, Chief Operating, Scientific Officer
- Michael Krachon, Vice President of Sales and Marketing
- Jennifer Streeter, Vice President - Human Resources
- Alan Hoffmann, Independent Director
- Michael W. McCormick, Independent Director
- Philip J. Vitale M.D., Independent Director
Has IsoRay been receiving favorable news coverage?
Media headlines about ISR stock have trended somewhat positive this week, Accern reports. Accern scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. IsoRay earned a coverage optimism score of 0.14 on Accern's scale. They also assigned media headlines about the healthcare company an impact score of 47.59 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
How do I buy shares of IsoRay?
Shares of ISR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is IsoRay's stock price today?
One share of ISR stock can currently be purchased for approximately $0.44.
How big of a company is IsoRay?
IsoRay has a market capitalization of $24.87 million.
How can I contact IsoRay?
IsoRay's mailing address is 350 Hills St Ste 106, RICHLAND, WA 99354-5511, United States. The healthcare company can be reached via phone at +1-509-3751202.
MarketBeat Community Rating for IsoRay (ISR)
MarketBeat's community ratings are surveys of what our community members think about IsoRay and other stocks. Vote "Outperform" if you believe ISR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ISR will underperform the S&P 500 over the long term. You may vote once every thirty days.
IsoRay (NYSEAMERICAN:ISR) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for IsoRay in the last 12 months. Their average twelve-month price target is $1.50, suggesting that the stock has a possible upside of 240.91%. The high price target for ISR is $2.00 and the low price target for ISR is $1.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $1.50 | $2.00 | $3.00 | $3.00 |
| Price Target Upside: | 240.91% upside | 354.55% upside | 597.67% upside | 455.45% upside |
IsoRay (NYSEAMERICAN:ISR) Consensus Price Target History
IsoRay (NYSEAMERICAN:ISR) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
IsoRay (NYSEAMERICAN:ISR) Earnings History and Estimates Chart
IsoRay (NYSEAMERICAN ISR) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 2/8/2018 | After Market | ($0.02) | ($0.03) | | $1.54 million | View | Listen |  |
| 11/14/2017 | Q1 2018 | | ($0.03) | | $1.21 million | View | N/A | |
| 9/28/2017 | Q4 2017 | ($0.01) | ($0.03) | | $1.37 million | View | N/A | |
| 5/10/2017 | Q3 2017 | | ($0.02) | | $1.28 million | View | N/A | |
| 2/8/2017 | Q2 2017 | | ($0.03) | | $1.03 million | View | N/A | |
| 11/9/2016 | Q1 2017 | | ($0.03) | | $1.08 million | View | N/A | |
| 9/8/2016 | Q416 | | ($0.02) | | $1.12 million | View | N/A | |
| 5/10/2016 | Q316 | | ($0.02) | $1.16 million | $1.20 million | View | N/A | |
| 2/9/2016 | Q216 | | ($0.02) | $1.07 million | $1.19 million | View | N/A | |
| 11/10/2015 | Q116 | ($0.01) | ($0.02) | $1.04 million | $1.46 million | View | N/A | |
| 9/15/2015 | Q4 | ($0.01) | ($0.02) | | $1.34 million | View | N/A | |
| 5/18/2015 | Q3 | ($0.01) | ($0.02) | $1.13 million | $1.16 million | View | N/A | |
| 2/18/2015 | Q215 | ($0.02) | ($0.02) | | $1.07 million | View | N/A | |
| 9/30/2014 | Q4 2014 | | ($0.03) | | $0.95 million | View | N/A | |
| 5/16/2014 | Q314 | ($0.03) | ($0.05) | $1.13 million | $1.13 million | View | N/A | |
| 2/18/2014 | Q2 2014 | | ($0.02) | | $1.09 million | View | N/A | |
| 11/14/2013 | Q1 | | ($0.06) | $1.06 million | $1.05 million | View | N/A | |
| 9/30/2013 | Q4 2013 | ($0.03) | ($0.03) | | $1.24 million | View | N/A | |
| 5/15/2013 | Q313 | ($0.03) | ($0.02) | $1.12 million | $1.25 million | View | N/A | |
| 2/14/2013 | Q2 2013 | ($0.03) | ($0.03) | $1.32 million | $0.9455 million | View | N/A | |
| 11/14/2012 | Q113 | ($0.03) | ($0.03) | $1.55 million | $1.06 million | View | N/A | |
| 9/28/2012 | Q4 2012 | ($0.03) | ($0.03) | | | View | N/A | |
| 5/15/2012 | Q3 2012 | ($0.03) | ($0.03) | | | View | N/A | |
| 2/15/2012 | Q2 2012 | | ($0.03) | | | View | N/A | |
| 11/15/2011 | Q1 2012 | ($0.03) | ($0.04) | | | View | N/A | |
| 9/28/2011 | Q4 2011 | | ($0.03) | | | View | N/A | |
| 5/16/2011 | Q3 2011 | ($0.03) | ($0.03) | | | View | N/A | |
| 2/15/2011 | Q2 2011 | ($0.04) | ($0.03) | | | View | N/A | |
| 11/16/2010 | Q1 2011 | ($0.05) | ($0.04) | | | View | N/A | |
| 9/28/2010 | Q4 2010 | ($0.05) | ($0.05) | | | View | N/A | |
| 5/12/2010 | Q3 2010 | ($0.04) | ($0.05) | | | View | N/A | |
| 2/16/2010 | Q2 2010 | ($0.03) | ($0.04) | | | View | N/A | |
| 11/16/2009 | Q1 2010 | ($0.05) | ($0.04) | | | View | N/A | |
| 9/24/2009 | Q4 2009 | ($0.04) | ($0.05) | | | View | N/A | |
| 5/18/2009 | Q3 2009 | | ($0.06) | | | View | N/A | |
| 2/17/2009 | Q2 2009 | ($0.08) | ($0.07) | | | View | N/A | |
| 11/13/2008 | Q1 2009 | ($0.08) | ($0.08) | | | View | N/A | |
| 5/13/2008 | Q3 2008 | | ($0.09) | | | View | N/A | |
| 2/11/2008 | Q2 2008 | ($0.09) | ($0.12) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
IsoRay (NYSEAMERICAN:ISR) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
IsoRay (NYSEAMERICAN ISR) Insider Trading and Institutional Ownership History
IsoRay (NYSEAMERICAN ISR) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/14/2018 | Philip J Vitale | Director | Buy | 10,000 | $0.44 | $4,400.00 | 80,000 | |
| 3/1/2018 | Thomas C Lavoy | CEO | Buy | 50,000 | $0.44 | $22,000.00 | | |
| 11/24/2017 | Mark John Austin | Insider | Buy | 2,040 | $0.49 | $999.60 | 2,000 | |
| 11/21/2017 | Mark John Austin | Insider | Buy | 5,400 | $0.48 | $2,592.00 | 2,000 | |
| 11/20/2017 | Michael Krachon | VP | Buy | 55,000 | $0.50 | $27,500.00 | 19,609 | |
| 11/16/2017 | Philip J Vitale | Director | Buy | 30,000 | $0.44 | $13,200.00 | | |
| 3/10/2017 | Thomas C Lavoy | CEO | Buy | 20,000 | $0.53 | $10,600.00 | 183,523 | |
| 1/4/2017 | Philip J Vitale | Director | Buy | 20,000 | $0.66 | $13,200.00 | 37,200 | |
| 12/8/2016 | Alan Hoffmann | Director | Buy | 20,000 | $0.57 | $11,400.00 | | |
| 11/17/2016 | Thomas C Lavoy | CEO | Buy | 20,000 | $0.60 | $12,000.00 | 163,523 | |
| 3/17/2016 | Thomas C Lavoy | CEO | Buy | 13,294 | $0.90 | $11,964.60 | 143,523 | |
| 3/11/2016 | Philip J Vitale | Director | Buy | 10,000 | $0.93 | $9,300.00 | 20,000 | |
| 3/11/2016 | Thomas C Lavoy | CEO | Buy | 36,706 | $0.89 | $32,668.34 | 118,528 | |
| 3/8/2016 | Michael W Mccormick | Director | Buy | 22,000 | $0.87 | $19,140.00 | 22,000 | |
| 11/12/2015 | Dwight William Babcock | CEO | Buy | 25,000 | $1.27 | $31,750.00 | 326,402 | |
| 6/9/2015 | Dwight William Babcock | CEO | Buy | 10,000 | $1.53 | $15,300.00 | | |
| 3/6/2015 | Thomas C Lavoy | Director | Buy | 10,000 | $1.66 | $16,600.00 | | |
| 3/5/2015 | Philip J Vitale | Director | Buy | 10,000 | $1.80 | $18,000.00 | | |
| 3/3/2015 | Dwight William Babcock | CEO | Buy | 10,029 | $1.51 | $15,143.79 | | |
| 11/1/2013 | Dwight William Babcock | CEO | Buy | 25,000 | $0.53 | $13,250.00 | | |
| 11/28/2012 | Thomas C Lavoy | Director | Buy | 18,100 | $0.49 | $8,869.00 | | |
| 11/21/2012 | Dwight William Babcock | CEO | Buy | 10,100 | $0.40 | $4,040.00 | | |
| 11/19/2012 | Dwight William Babcock | CEO | Buy | 4,800 | $0.37 | $1,776.00 | | |
| 11/19/2012 | Robert R Kauffman | Director | Buy | 25,000 | $0.38 | $9,500.00 | | |
| 11/16/2012 | Dwight William Babcock | CEO | Buy | 35,100 | $0.42 | $14,742.00 | | |
(Data available from 1/1/2013 forward)
IsoRay (NYSEAMERICAN ISR) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | IsoRay to Present at the Planet MicroCap Showcase 2018 on April 25 in Las Vegas, NV
finance.yahoo.com - April 19 at 9:12 AM |
| IsoRay Announces Preliminary Third Quarter Fiscal 2018 Revenue of $1.57 Million, 23% Year-over-Year Increase
finance.yahoo.com - April 18 at 9:17 AM |
 | IsoRay (ISR) Coverage Initiated at Ascendiant Capital Markets
www.americanbankingnews.com - April 2 at 2:38 PM |
 | Benzinga's Top Upgrades, Downgrades For April 2, 2018
www.benzinga.com - April 2 at 9:44 AM |
 | Pivotal Research Starts IsoRay, Inc. (ISR) at Buy Citing Valuation
www.streetinsider.com - April 2 at 9:44 AM |
| UPDATE: Ascendiant Starts IsoRay, Inc. (ISR) at Buy Citing Valuation
www.streetinsider.com - April 2 at 9:44 AM |
| IsoRay, Inc. (ISR) CEO Thomas C. Lavoy Acquires 50,000 Shares
www.americanbankingnews.com - March 2 at 7:34 PM |
| IsoRay (ISR) Given a $2.00 Price Target at Maxim Group
www.americanbankingnews.com - February 14 at 10:40 PM |
| IsoRay (ISR) Announces Earnings Results
www.americanbankingnews.com - February 10 at 11:44 AM |
| IsoRay, Inc. (ISR) Sees Large Drop in Short Interest
www.americanbankingnews.com - February 9 at 6:56 PM |
| IsoRay Announces Second Quarter Fiscal 2018 Revenue of $1.54 Million, 50% Second Quarter-Over-Second Quarter Increase
finance.yahoo.com - February 8 at 4:16 PM |
| IsoRay (ISR) PT Set at $3.00 by Maxim Group
www.americanbankingnews.com - February 8 at 3:18 PM |
| IsoRay Announces Study Published in Cureus entitled, “Resection Cavity Contraction Effects in the Use of Radioactive Sources (1-25 versus Cs‑131) for Intra-Operative Brain Implants”
finance.yahoo.com - February 8 at 8:48 AM |
| Was IsoRay Inc’s (NYSEMKT:ISR) Earnings Decline A Part Of Broader Industry Downturn?
finance.yahoo.com - February 6 at 9:15 AM |
| IsoRay Announces Second Quarter Fiscal 2018 Earnings Conference Call
finance.yahoo.com - January 31 at 9:36 AM |
| IsoRay (ISR) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - January 30 at 3:46 AM |
| IsoRay (ISR) Given a $3.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - January 24 at 2:02 PM |
| IsoRay Announces Preliminary Second Quarter F2018 Revenue of $1.54 Million, 50% Year-over-Year Increase
finance.yahoo.com - January 24 at 9:47 AM |
| IsoRay Announces Case Report Publication Discussing Focal Radiation Treatment of Brain Metastases with Cesium-131
finance.yahoo.com - January 9 at 10:29 AM |
| IsoRay Announces Manufacturing and Supply Agreement with GT Medical Technologies for GammaTile™ Radiation Therapy System
finance.yahoo.com - January 8 at 11:05 AM |
| ETFs with exposure to IsoRay, Inc. : December 26, 2017
finance.yahoo.com - December 26 at 12:49 PM |
| ETFs with exposure to IsoRay, Inc. : December 7, 2017
finance.yahoo.com - December 7 at 3:31 PM |
| IsoRay, Inc. :ISR-US: Earnings Analysis: Q1, 2018 By the Numbers : December 1, 2017
finance.yahoo.com - December 1 at 11:57 AM |
| IsoRay to Present at the 10th Annual LD Micro Main Event
finance.yahoo.com - November 28 at 9:46 AM |
| IsoRay, Inc. (ISR) VP Buys $27,500.00 in Stock
www.americanbankingnews.com - November 21 at 4:41 PM |
| Maxim Group Reiterates "$3.00" Price Target for IsoRay, Inc. (ISR)
www.americanbankingnews.com - November 19 at 5:38 PM |
| Philip J. Vitale Acquires 30,000 Shares of IsoRay, Inc. (ISR) Stock
www.americanbankingnews.com - November 17 at 9:50 PM |
| IsoRay reports 1Q loss
finance.yahoo.com - November 17 at 8:18 AM |
| IsoRay, Inc. (ISR) Issues Earnings Results
www.americanbankingnews.com - November 15 at 12:56 PM |
 | IsoRay Announces First Quarter Fiscal 2018 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 15 at 3:21 AM |
| IsoRay, Inc. to Host Earnings Call
finance.yahoo.com - November 15 at 3:21 AM |
| IsoRay Announces First Quarter Fiscal 2018 Financial Results
finance.yahoo.com - November 15 at 3:21 AM |
IsoRay (NYSEAMERICAN:ISR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
IsoRay (NYSEAMERICAN:ISR) Income Statement, Balance Sheet and Cash Flow Statement
IsoRay (NYSEAMERICAN ISR) Stock Chart for Monday, April, 23, 2018
Loading chart…
